Search for:

A primary goal of the ARLG is to train the next generation of researchers who will help reduce the public health threat of antibacterial resistance.

LEARN MORE

Home
About
Publications
News and Events
- Events
- Newsletters
How to Apply
SDMC
Lab Center
Studies
Resources
- For Patients and the Community
- Summary of Results

ARLG

Antibacterial Resistance Leadership Group

December 2025

Posted on December 17, 2025 by AM

The December 2025 newsletter features updates on the PHAGE and DOTS (Dalbavancin as an an Option for Treatment of Staphylococcus aureus bacteremia) studies as well as a clinical trial site spotlight on the University of North Carolina. The newsletter also includes a mentee spotlight, study milestones, recent publications, and more ARLG network news.

This entry was posted in Newsletter. Bookmark the permalink.

← ARLG Steering Committee Members Receive Recognition for Significant Contributions to AMR

Bacteriophage Therapy →

Home
About the ARLG
Publications
About the Laboratory Center
Studies

ARLG is supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content of this website is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Subscribe to the ARLG newsletter to stay connected

Privacy Statement

WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.